Drug Profile

Niraparib - Janssen/Merck/GSK

Alternative Names: GSK-3985771; JNJ-64091742; MK-4827; niraparib hydrochloride; Zejula; ZL 2306

Latest Information Update: 28 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Merck & Co
Developer Bayer; Dana-Farber Cancer Institute; Emory University; European Network of Gynaecological Oncological Trial Groups; European Organisation for Research and Treatment of Cancer; Georgetown University; GSK; Hunan Cancer Hospital; Janssen; Katholieke Universiteit Leuven; Massachusetts General Hospital; Medica Scientia Innovation Research; Merck & Co; Myriad Genetics; NeoGenomics; Novocure Limited; OncoQuest; Resolution Bioscience; Sarcoma Alliance for Research through Collaboration; Takeda; Tempus; TESARO; Thomas Jefferson University; University Health Network; University of Florida; University of Kansas Medical Center; University of Oklahoma; University of Pennsylvania; University of Texas M. D. Anderson Cancer Center; University of Turin; University of Utah; ZAI Lab
Class Antineoplastics; Benzamides; Indazoles; Piperidines; Small molecules
Mechanism of Action Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase-1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Ovarian cancer
New Molecular Entity Yes

Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Phase III Breast cancer; HER2 negative breast cancer; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer
Phase II Cervical cancer; Cholangiocarcinoma; CNS cancer; Endometrial cancer; Glioblastoma; Mesothelioma; Neuroendocrine tumours; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer; Uveal melanoma
No development reported Ewing's sarcoma; Gastric cancer; Haematological malignancies

28 Jul 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, In adolescents, In children, In infants, Second-line therapy or greater) in Spain (PO, Liquid)
28 Jul 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, In adolescents, In children, In infants, Second-line therapy or greater) in Spain (PO, Tablet)
11 Jun 2025 GlaxoSmithKline terminates a phase I trial in Solid tumours (Combination therapy, In infants, In children, In adolescents, Second-line therapy or greater) in Czech Republic, France, Germany, Hungary, Spain, the United Kingdom (IV) (NCT04544995)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com